Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220013/S029

TactiFlex Ablation Catheter, Sensor Enabled (A-TFSE-D; A-TFSE-F; A-TFSE-J; A-TFSE-DD; A-TFSE-DF; A-TFSE-FF; A-TFSE-FJ;

ABBOTT MEDICAL · Decision date May 15, 2026

FDA DECISIONP220013/S029

What did the FDA decide?

FDA records P220013/S029 as a supplement to PMA P220013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 15, 2026.

FDA approval order statement

new equipment for the implementation of an automated inspection process for catheter assembly and electrical testing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
May 15, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220013/S029
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
OK30
Decision date
May 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

For the original device and its historical approval scope, see PMA P220013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220013 · Original PMA

    TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C

  2. P220013/S020 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled

  3. P220013/S021 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled

  4. P220013/S023 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled (TactiFlex SE)

  5. P220013/S025 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled (TactiFlex SE)

  6. P220013/S026 · Related supplement

    TactiFlex Sensor Enabled

  7. P220013/S027 · Related supplement

    TactiFlex Ablation Catheter SE (A-TFSE-D, A-TFSE-F, A-TFSE-J, A-TFSE-DD, A-TFSE-DF, A-TFSE-FF, A-TFSE-FJ, A-TFSE-JJ, A-T

  8. P220013/S029 received

    Application receipt date recorded by FDA.

  9. P220013/S029 · FDA decision

    30-Day Notice

  10. P220013/S022 · Related supplement

    TactiFlex Sensor Enabled Ablation Catheter

  11. P220013/S032 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled (TactiFlex SE)

  12. P220013/S031 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled

  13. P220013/S030 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C

  14. P220013/S033 · Related supplement

    TactiSys Quartz Equipment; Ampere Generator

  15. P220013/S028 · Related supplement

    TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM

  16. P220013/S034 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled

Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220013

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalMay 18, 2023FDA
ABBOTT MEDICALPMA supplementAug 1, 2025FDA
ABBOTT MEDICALPMA supplementAug 7, 2025FDA
ABBOTT MEDICALPMA supplementOct 30, 2025FDA
ABBOTT MEDICALPMA supplementJan 8, 2026FDA
ABBOTT MEDICALPMA supplementJan 15, 2026FDA
ABBOTT MEDICALPMA supplementFeb 3, 2026FDA
ABBOTT MEDICALPMA supplementMay 28, 2026FDA
ABBOTT MEDICALPMA supplementMay 29, 2026FDA
ABBOTT MEDICALPMA supplementJun 5, 2026FDA
ABBOTT MEDICALPMA supplementJul 23, 2026FDA
ABBOTT MEDICALPMA supplementAug 7, 2026FDA
ABBOTT MEDICALPMA supplementSep 4, 2026FDA
ABBOTT MEDICALPMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code OAE

Product / regulatory recordCompanyPathwayDecision dateSource
STOP Persistent AFP100010/S154
Medtronic Cryocath, LPPMA supplementSep 25, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
TX eco CableP210027/S017
Biosense Webster, Inc.PMA supplementAug 17, 2026FDA
St Jude MedicalPMA supplementAug 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records